29 maj: Solkystens luksuriøse oase – Marbella Club
31 maj: Skattereform: Ny kapitalpension er generationsrøveri til 150 mia...
29-05-2012 22:39:00

UPDATE: J&J Unit Gets FDA Warning Letter On K-Y Vaginal Moisturizer

Relateret indhold

(Updates with McNeil statement starting in the third paragraph.)

--FDA warns J&J unit on failure to properly investigate some consumer complaints

--Most of the letter details problems related to K-Y vaginal moisturizer

--FDA says a reporting problem related to O.B. Tampons has been adequately addressed

By Jennifer Corbett Dooren

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration said a Johnson & Johnson (JNJ) unit didn't properly investigate consumer complaints related to a vaginal moisturizer.

The agency, in a warning letter dated May 22, said the company received more than 200 complaints about K-Y liquibeads vaginal moisturizer, which is made by McNeil PPC Inc., from June 25, 2010, through Dec. 12, 2011. The agency said the complaints included reports of the product not dissolving or having an uncharacteristic consistency or texture. FDA said some of the complaints were closed without being investigated by the company. McNeil also didn't adequately investigate some complaints that contained an incorrect lot number, according to FDA.

In a statement, McNeil said it takes the issues raised by FDA seriously. "We will respond fully to their concerns and take whatever steps are needed to resolve these issues," the company said.

The warning letter was posted to the FDA's website on Tuesday. The letter stems from an inspection conducted by the FDA of a McNeil facility in Skillman, N.J. on Dec. 12, 2011 through Jan. 19, 2012.

The FDA also said the company was late in submitting a report about a person being diagnosed with toxic shock syndrome after using an O.B. Tampon, also made by McNeil. However, the FDA said the company had adequately responded to the agency's concerns about that report.

Johnson & Johnson's McNeil Consumer Healthcare unit has been working to address manufacturing problems that led to recalls of Tylenol and other over-the-counter products starting in 2009. Three of the company's manufacturing plants were placed under an FDA consent decree last year and one of the plants, in Fort Washington, Pa., is still shut down.

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com

(END) Dow Jones Newswires

May 29, 2012 16:39 ET (20:39 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Tivoli/CEO: Ny sæson og Tivoli Hjørnet øger omsætningen

23-04-2018 13:39:42
Den nye sæson hos forlystelsesparken Tivoli, Vinter I Tivoli, har sammen med åbningen af Tivoli Hjørnet bidraget til, at omsætningen er steget i første kvartal 2018.Det vurderer Lars Liebst, der er administrerende direktør i Tivoli. - Vi har haft åbent til Vinter i Tivoli og åbnet vores hjørne, og det har været gode ting. Det kan man se på omsætningen, siger Lars Liebst til Ritzau Finans.Nettoomsæ..

Vestas-konkurrent: Møllepriser er faldet 13 pct. på årsbasis

23-04-2018 07:00:55
Den amerikanske Vestas-konkurrent GE Renewable Energy melder om fortsat prispres, hvilket selskabet forsøger at kompensere for gennem omkostningsreduktioner. I første kvartal faldt priserne på nye mølleenheder til ordrebogen med 13 pct. i forhold til samme periode sidste år. Det sagde finansdirektøren for General Electric, som GE Renewable Energy er en del af, Jamie Miller, fredag på en telekonfer..

Bavarian: Udenlandske kapitalfonde øger væddemålet på kursfald

20-04-2018 16:36:15
En række kapitalfonde har onsdag og torsdag øget sine shortpositioner i biotekselskabet Bavarian Nordic. Det viser en række indberetninger til Finanstilsynet. Torsdag har Capital Partners øget sin shortposition til 0,62 pct. af aktierne fra 0,54 pct. Ligeledes har AHL Partners øget sin shortposition til 1,31 pct. af Bavarian-aktierne. Tidligere havde kapitalfonden shortet 1,20 pct.Arrow Street øge..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Bavarian-aktien har oplevet markant shortangreb efter regnskab
2
Vestas-konkurrent: Møllepriser er faldet 13 pct. på årsbasis
3
Aktier/tendens: Topdanmark kan få hovedrolle i neutralt marked
4
Pandora/Carnegie: Løfter kursmålet til 700 kr.
5
Milliardsalg af L'easy vakler - citat

Relaterede aktiekurser

Johnson & Johnson 126,83 0,1% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. april 2018 06:56:50
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180423.5 - EUROWEB7 - 2018-04-24 06:56:50 - 2018-04-24 06:56:50 - 1 - Website: OKAY